Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$198.51 – $352.00
50% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.03B | $5.37B | $10.11B | $8.48B | $14.51B | $16.47B | $21.53B | $3.85B |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $226.0M | $985.0M | $319.9M |
| Gross profit | $3.03B | $5.37B | $10.11B | $8.42B | $14.51B | $16.25B | $20.54B | $3.53B |
| Gross margin | 100.0% | 100.0% | 100.0% | 99.2% | 100.0% | 98.6% | 95.4% | 91.7% |
| R&D | $1.43B | $2.39B | $3.14B | $4.18B | $5.56B | $7.63B | $9.75B | $1.61B |
| Operating income | $1.38B | $2.64B | $6.31B | $2.95B | $6.27B | $5.32B | $6.98B | $1.29B |
| EBITDA | $1.70B | $3.00B | $6.16B | $3.15B | $7.33B | $5.99B | $9.70B | $1.37B |
| Net income | $1.47B | $2.17B | $4.76B | $2.96B | $5.45B | $4.35B | $7.84B | $996.9M |
| Net margin | 48.7% | 40.4% | 47.1% | 34.9% | 37.6% | 26.4% | 36.4% | 25.9% |
| EPS (diluted) | 23.73 | 34.04 | 72.22 | 45.54 | 82.59 | 66.02 | 121.36 | 15.90 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4.3B | $11.38 | $10.45–$12.73 | 10 |
| 2027 | $5.1B | $17.00 | $15.62–$19.02 | 5 |
| 2028 | $6.1B | $25.39 | $23.32–$28.40 | 7 |
| 2029 | $6.1B | $24.94 | $22.91–$27.89 | 10 |
Forward consensus · source: Financial Modeling Prep
GENMAB A/S DKK
No one on the platform currently holds GNMSF.
No tracked institution reports a position in GNMSF as of their last filing.
No one on the platform has traded GNMSF yet.
| $13.4B |
| — |
| IVBXFInnovent Biologics, Inc. | $11.03 | +7.36% | $19.1B | — |
| ORINYOrion Oyj | $41.27 | +9.09% | $23.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Trading at 2.6× earnings vs its 5.6× historical median P/E.
Fair value ≈ $583.49 · price $275.00 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.